Trials / Completed
CompletedNCT00900588
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Sinovac Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic influenza A vaccine (H5N1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) |
Timeline
- First posted
- 2009-05-13
- Last updated
- 2009-08-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00900588. Inclusion in this directory is not an endorsement.